Initializing download.-
By Thomas A. Ciulla, MD, MBA, FASRS
Indiana University School of Medicine - Uploaded on Aug 10, 2014.
- Last modified by Caroline Bozell on Aug 11, 2014.
- Rating
- Appears in
- Bevacizumab for persistent proliferative diabetic retinopathy
- Condition/keywords
- proliferative diabetic retinopathy (PDR), intravitreal bevacizumab
- Description
- Intravitreal bevacizumab (1.25 mg) was administered intravitreally. When she returned 8 weeks later, her macular edema resolved and NV regressed.
---thumb.jpg/image-square;max$79,0.ImageHandler "PDR Neovacularization of the Disc")
---thumb.JPG/image-square;max$79,0.ImageHandler "Neovascularisation Disc")
---thumb.JPG/image-square;max$79,0.ImageHandler "Proliferative Diabetic Retinopathy With Neovascularization - Fundus photograph")
---thumb.JPG/image-square;max$79,0.ImageHandler "Proliferative Diabetic Retinopathy With Neovascularization - Red-Free")
---thumb.JPG/image-square;max$79,0.ImageHandler "Proliferative Diabetic Retinopathy With Neovascularization - Red-Free")